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Abstract
OBJECTIVE: To investigate the effect of didroval-
trate on L-type calcium current (ICa-L) in rabbit ven-
tricular myocytes.
METHODS: We used the whole cell patch clamp re-
cording technique.
RESULTS: Didrovaltrate at concentrations of 30 μg/
L and 100 μg/L significantly decreased peak ICa-L
(ICa-Lmax) from (6.01±0.48) pA/pF to (3.45±0.27) pA/pF
and (2.16±0.19) pA/pF (42.6% and 64.1%, n=8, P<
0.01), respectively. Didrovaltrate shifted upwards
the current-voltage curves of ICa-L without changing
their active, peak and reverse potentials. Didroval-
trate affected the steady-state inactivation of ICa-L.
The half activation potential (V1/2) was significantly
shifted from (-26±2) to (-36±3) mV (n=6, P<0.05),
with a significant change in the slope factor (k)
(from 8.8±0.8 to 11.1±0.9, n=6, P<0.05). Didroval-
trate did not affect the activation curve.
CONCLUSION: Didrovaltrate blocks ICa-L in a concen-
tration-dependent manner and probably inhibits
ICa-L in its inactive state, which may contribute to its
cardiovascular effect.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
The mildly sedating effects of valerian (Valeriana offici-
nalis) and its many related Valerianaceae were noted by
Greek, Roman, Chinese, and Indian scholars for more
than 1000 years. The chemical composition of valerian
includes sesquiterpenes of the volatile oil (including va-
leric acid), iridoids (valepotriates), alkaloids, furanofu-
ran lignans, and free amino acids, such as γ-aminobu-
tyric acid (GABA), tyrosine, arginine, and glutamine.
Although the sesquiterpene components of the volatile
oil are believed to be responsible for most of valerian's
biological effects, it is likely that all of the active con-
stituents of valerian act in a synergistic manner to pro-
duce a clinical response.1
Research into the physiological activity of individual
components of valerian has demonstrated direct seda-
tive effects (valepotriates and valeric acid) and interac-
tion with neurotransmitters, such as GABA (valeric ac-
id and unknown fractions).2,3 In recent years, cardiovas-
cular effects of valerian extract, such as hypotensive,
negative inotropic, and antiarrhythmic actions, have
been reported in many studies.4-6 However, the mecha-
nisms underlying the beneficial effects of valerian ex-
tract on hearts have not been clearly established. It is
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postulated that valerian extract has effects on the volt-
age-dependent ICa-L. Therefore, the purpose of the pres-
ent study was to clarify the effects of valerian extract
(didrovaltrate, one of the valepotriates) on the volt-
age-dependent ICa-L in rabbit cardiac myocytes.
MATERIALS ANDMETHODS
Cell isolation
Single rabbit ventricular myocytes were isolated by an
enzymatic dissociation procedure modified from Tyt-
gat.7. New Zealand White rabbits of either sex, weigh-
ing 1.0-2.0 kg (Experimental Animal Centre of Medi-
cal College, Xiamen University), were anesthetized
with 1 mL/kg intramuscularly injected Hypnorm (10
mg/mL fluanisone and 0.315 mg/mL fentanyl citrate;
Janssen Pharmaceutics, Tilburg, The Netherlands) and
0.1 mL heparin sodium (5000 U/mL) was injected in-
travenously. The heart was rapidly removed and mount-
ed on a Langendorff perfusion apparatus. It was retro-
gradely perfused through the aorta with normal Ty-
rode's solution for 10 min, followed by an additional
10 min of perfusion with Ca2 +-free Tyrode's solution.
Perfusion was then switched to Ca2+-free Tyrode's solu-
tion containing collagenase II (Sigma-Aldrich, USA)
for 15 min.
The enzymatic solution was recirculated. All solutions
were saturated with 100% O2 and the temperature was
maintained at 37°C. Subsequently, the ventricles were
minced and gently agitated in a beaker with low-Ca2 +
Tyrode's solution to obtain single myocytes. The calci-
um concentration was then increased stepwise by re-
placing approximately 75% of the low-Ca2+ Tyrode's so-
lution by normal Tyrode's solution. This procedure
was repeated four times at intervals of 10 min. The
cells were placed in a high-K+ storage solution and gen-
tly triturated with a Pasteur pipette. Isolated myocytes
were kept in the medium for at least 1 h at room tem-
perature (20-22°C) before use.
Solutions and drugs
The normal Tyrode's solution contained (mM): NaCl
140, KCl 5.4, MgCl2 1.0, HEPES 5.0, and glucose 10.
The pH was adjusted to 7.4 with NaOH. The pipette
solution contained (mM): CsOH 110, TEACl 15,
CsCl 20, MgCl2 1.0, egtazic acid (EGTA, Sigma-Al-
drich, USA) 5.0, pyruvic acid 5.0, MgATP 5.0, and
HEPES 5.0 at pH 7.3 (adjusted with Tris). The exter-
nal solution contained (mM): NMDG-Cl 140, MgCl2
1.0, CaCl2 1.8, HEPES 5.0, glucose 10, tetrodotoxin
(TTX; Hebei Aquatic product Research Institute), and
0.002 and 4-aminopyridine (4-AP, Sigma-Aldrich,
USA) 2.0. The pH was adjusted to 7.4 with NMDG.
KB solution contained (mM): KOH 110, taurine 10,
oxalic acid 10, glutamic acid 70, KCl 25, KH2PO4 10,
EGTA 5.0, HEPES 5.0, and glucose 10. The pH was
adjusted to 7.4 with KOH. Other chemical reagents
were purchased from China. Didrovaltrate was a kind
gift from Professor Xue Cunkuan of the Geriatrics In-
stitute of Huazhong University of Science & Technolo-
gy.
Electrical recordings
Membrane currents and action potentials were record-
ed using an EPC-9 patch clamp amplifier (HEAK, Ger-
many). Myocytes adhering to glass coverslips were
placed in a small chamber mounted on the stage of an
inverted microscope and superfused at 1.5 mL/min at
room temperature (20-22°C). Action potential record-
ings were performed at 37°C. Other experiments were
performed at room temperature. Only rod-shaped sin-
gle cells that were quiescent and exhibiting well de-
fined cross-striations were studied. After establishment
of whole-cell configuration and measurement of cell ca-
pacitance, series resistance (≤10 MΩ) was compensated
by 50% to 70%. Junction potentials under these condi-
tions were -3mV and corrected. (ICa-L) was elicited by a
series of depolarization steps of 200 ms duration ap-
plied in 10-mV increments from a holding potential
of -40 mV. Action potentials were recorded in cur-
rent-clamp mode. Borosilicate glass electrodes (1.0 mm
OD) were pulled with a vertical puller (PB-7, Nar-
ishige, Tokyo, Japan) and had a resistance of 2-3 MΩ
when filled with electrode internal solution. Data ac-
quisition and analysis were carried out using pClamp
software (Axon Instruments Inc., Foster City, CA,
USA). Current signals were filtered at 3 kHz and sam-
pled at a frequency of 10 kHz. Peak ICa amplitudes
were estimated as the difference between the maximal
inward current and zero-current.
Statistical analyses
Data are expressed as the mean±SD. Statistical analysis
was performed using paired t-tests to determine statisti-
cal significance. A probability of P≤0.05 was consid-
ered significant.
RESULTS
Effects of didrovaltrate on voltage-dependent ICa-L
The effects of didrovaltrate on voltage-dependent ICa-L
were examined in single ventricular myocytes (Figure
1). The membrane potential was maintained at -40
mV, and command voltage pulses (200 ms in duration)
from –40 mV to +60 mV were applied at 0.2 Hz.
Didrovaltrate at 30 μg/L and 100 μg/L significantly
decreased peak ICa-L (ICa-Lmax) from (6.01±0.48) pA/pF to
(3.45 ± 0.27) pA/pF and (2.16 ± 0.19) pA/pF (42.6%
and 64.1%, n=8, P<0.01), respectively. After washout,
ICa-L gradually returned to near control levels. The
inhibitory effect was concentration dependent and was
easily recovered after washout with Tyrode's solution for
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5 min.
Figure 1 Effects of didrovaltrate on voltage-dependent ICa-L
Cells were maintained at –40 mV, and command voltage
pulses (200 ms in duration) were applied at 0.2 Hz from –
40 mV to +60 mV. Superimposed original current traces re-
corded in a single ventricular myocytes are shown. Trace (A):
control. Trace (B): in the presence of didrovaltrate 30 μg /L.
Trace (C): in the presence of didrovaltrate 100 μg/L. Trace
(D): after washout.
Effect of didrovaltrate on the current-voltage
relationship of ICa-L
The current-voltage relationship of ICa-L and the didro-
valtrate current-voltage (I-V) curve of L-type current
were obtained by a number of depolarizing step pulses
(200 ms) from the holding potential of – 40 mV to
test potentials between –40 mV and 60 mV. The test
step pulses were delivered in 10 mV increments. ICa-L
was activated at –30 mV and the peak amplitude oc-
curred at the potential of 0 mV. Didrovaltrate at 30 μg/
L and 100 μg/L shifted the I-V curve upwards without
changes in their active, peak and reverse potentials (Fig-
ure 2).
Effect of didrovaltrate on the steady-state
inactivation and activation of ICa-L
The effect of didrovaltrate on the steady-state inactiva-
tion of ICa-L is shown in Figure 3. The results were well
fitted by the Boltzmann equation I/Imax=1/ [1 + exp
(Vm-V1/2/k)], where I/Imax is the ratio of ICa-L amplitude
to its maximal value, V1/2 is the voltage at which the
normalized ICa-L amplitude is 0.5, and k is the slope fac-
tor. A concentration of 100 μg/L didrovaltrate caused
a marked shift of the inactivation curve toward more
negative potentials, significantly shifting V1/2 from
(-26±2) mV to (-36±3) mV (n=6, P<0.05), with a sig-
nificant increase in k (from 8.8±0.8 to 11.1±0.9, n=6,
P<0.05). A concentration of 100 μg/L didrovaltrate
did not affect the activation curve (data not shown).
Figure 3 Effect of didrovaltrate on the steady-state inactiva-
tion curve of ICa-L
Currents were elicited by a 300 ms test pulse to +20 mV af-
ter 2 s of conditioning prepulses from–80 to +20 mV in 10
mV increments. Curves were obtained by simulating the
voltage dependent changes in I/Imax using the Boltzmann
equation: I/Imax=1/ [1 + exp (Vm-V1/2/k)]. A concentration of
100 μg/L didrovaltrate shifted V1/2 from (-26±2) mV to(-36±
3mV and k from 8.8±0.8 to 11.1±0.9 (n=6, P<0.05).
DISCUSSION
Our findings demonstrated that didrovaltrate pro-
duced voltage-dependent blockade of ICa-L in a concen-
tration-dependent manner. The steady-state inactiva-
tion kinetics of ICa-L were changed and the inactivation
curve of ICa-L shifted towards more negative potentials.
These findings indicated that didrovaltrate inhibited
ICa-L by its effect on inactivation kinetics.
Figure 2 Effects of didrovaltrate on the current-voltage rela-
tionship of ICa-L
Step pulses were applied in 10 mV increments from -40 mV
to 6 0mV. The holding potential was -40 mV. Each point is
the mean±s.d. of the current density (n=7 cells)
A
B
C
D
-40mv
-40mv
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Two types of calcium channel have been distinguished
on the basis of their electrophysiological and pharmaco-
logical characteristics in ventricular myocytes.8,9 The
physiological significance of the L-type calcium chan-
nel is better understood than that of the T-type calci-
um channel. Calcium influx through the L-type calci-
um channel is responsible for the upstroke of the ac-
tion potential in the sinoatrial node and atrioventricu-
lar node, and plays an important role in determining
the plateau and eventual spike-dome appearance of the
action potential in other cardiac cells. The L-type calci-
um channel is further responsible for the coupling be-
tween excitation and contraction, it induces release of
Ca2+ from the sarcoplasmic reticulum, and regulates in-
tracellular Ca2 + load. In this way, the L-type calcium
channel determines activity of a number of mitochon-
drial and cytoplasmic Ca2+-sensitive enzymes.10
The underground organs of members of the genus Va-
leriana (Valerianaceae), as well as related genera such as
Nardostachys, are used in the traditional medicine of
many cultures as mild sedatives and tranquillizers and
to aid the induction of sleep.11-13 The anticonvulsive,
sedative, and hypnotic effects have been variously at-
tributed to valeric acid, valeranone, and valepotriates.4
The chemical composition of valerian includes sesqui-
terpenes of the volatile oil (including valeric acid), iri-
doids (valepotriates), alkaloids, furanofuran lignans,
and free amino acids, such as GABA, tyrosine, argi-
nine, and glutamine. Although the sesquiterpene com-
ponents of the volatile oil are believed to be responsible
for most of valerian's biological effects, it is likely that
all of the active constituents of valerian act in a syner-
gistic manner to produce a clinical response.1 Research
into physiological activity of individual components
has demonstrated direct sedative effects (valepotriates
and valeric acid) and interaction with neurotransmit-
ters, such as GABA (valeric acid and unknown frac-
tions).2,3 In recent years, cardiovascular effects of valeri-
an extract, such as hypotensive, negative inotropic, and
antiarrhythmic effects, have been reported in some
studies.4-6 Our findings demonstrate that didrovaltrate
inhibits ICa-L, which may contribute to its cardiovascu-
lar effects.
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